Neurocrine Biosciences Inc $ 98.77 0 (0%)
NBIX News and Headlines - Neurocrine Biosciences Inc
Three more companies are going public to take advantage of this year's feeding frenzy for biotechs: Spruce Biosciences, Shattuck Labs and Kronos Bio Inc. All of them are to be listed on the Nasdaq.
As I wrote in a previous article on GuruFocus, at least 37 venture-backed North American life sciences companies have carried out IPOs year to date, raising a total of $6.7 billion, according to an article in Crunchbase. In all of 2019, 51 public offerings raised $5 billion.
Spruce, based in San Francisco, has filed for an $86 million IPO and will trade
During a May 6 earnings conference call, the head of business development and strategy for Neurocrine Biosciences Inc (NBIX) said the company was looking for other partnerships, similar to those it had recently struck with Xenon Pharmaceuticals Inc. (XENE) and Voyager Therapeutics Inc. (VYGR).
It didn’t take long for Neurocrine to find what it was looking for, announcing on Tuesday it had inked a $2 billion pact to license seven drugs from Takeda Pharmaceutical Co. Ltd. (TAK). The deal bulks up the Neurocrine pipeline, which is dominated by treatments for movement disorders, women's health and genetic diseases.
Shares of the
The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Intercept Pharmaceuticals Inc. (ICPT).
The New York-based biotech could certainly use a boost. At just over $65, the stock is off about 50% from its 52-week high. TipRanks reported that the 13 analysts following Intercept rated it a strong buy with a target price of $151, but those estimates appear to be pre-coronavirus so investors should view them skeptically.
Intercept is hoping the
These companies may attract the interest of investors because they have increased their capital spending significantly over the past five years. Such spending suggests that these companies likely have expectations for higher demand for their products and/or services, which would in turn produce higher sales.
Thus, investors may want to consider the following stocks as they are expected to post higher-than-average earnings per share (EPS) over the next five years following years of massive allocation of funds to capital spending for business growth.
Alibaba Group Holding
The first company that meets the above-listed criteria is Alibaba Group Holding Ltd (BABA),
As Peter Lynch noted in his book “One Up on Wall Street,” it wasn’t the gold diggers that turned significant profits during the California Gold Rush. It was the people who sold pickaxes and work clothes to the miners. In other words, you turn a profit when you have a product that is selling, not when you are still in the process of finding gold.
As medical science advances in leaps and bounds, you may have seen at least one person plugging up their bionic arm for charging at a big event. The technology doesn’t come cheap, but the companies
Further expanding his holdings in the health care space, billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed a 5.24% stake in biotech company Chiasma Inc. (CHMA) on Tuesday.
The guru’s Stamford, Connecticut-based hedge fund uses long, short, macro and systematic strategies to generate risk-adjusted returns.
According to GuruFocus Real-Time Picks, a Premium feature, Cohen invested in 1.6 million shares of the Waltham, Massachusetts-based company on July 29, dedicating 0.04% of the equity portfolio to the position. The stock traded for an average price of $5.56.
He previously sold out of a smaller
With the goal of generating superior risk-adjusted returns, the guru’s Stamford, Connecticut-based fund uses long, short, macro and systematic strategies.
The investor has a long history with the stock. After exiting a position in the first quarter, Cohen revealed in a Securities and Exchange Commission filing that he invested in 4.3 million shares of the California-based clinical-stage biopharmaceutical company on May 28.
The company, which develops therapies for
The biotech space provides ample opportunities for value. The recent market pullback, coupled with sector’s inherent ability to produce breakout companies makes it a good place to look for long-term value. San Diego-based Neurocrine Biosciences (NBIX) is a biotechnology firm specializing in the development of treatments for neurological and endocrine diseases and disorders.
Although the stock has had a rough few months, losing around 45% from its 2018 highs, Neurocrine’s strong pipeline could bring the company back in the long term.
On its most recent earnings call, Neurocrine posted total revenues of $151.8 million for the
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.
Three gurus are invested in Akebia Therapeutics Inc. (AKBA).
The company designs, manufactures and commercialize novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. It has a market cap of $589.31 million.
The stock is trading with a price-book (P/B) ratio of 2.55. The current price of $10.36 is 48.84% below its 52-week high and 16.01% above its 52-week low. Over the past 10 years, it has returned a loss of 61%.
The company’s largest shareholder among the gurus is
According to the GuruFocus All-In-One Screener, the following health care stocks have positions in gurus' portfolios.
Twenty-three gurus hold shares of Shire PLC ADR (SHPG).
The biotechnology company's brands include Vyvanse, Lialda and Adderall XR.
The company has a market cap of $46.12 billion; the stock is trading with a price-earnings (P/E) ratio of 56.90. The price of $151.84 is 27.43% below its 52-week high and 8.96% above its 52-week low. Over the past decade, it has returned a gain of 93%.
Neurocrine Biosciences (NBIX) announced in April that the company’s drug Ingrezza (valbenazine) has been approved by the U.S. Food and Drug Administration (FDA) for treating tardive dyskinesia (TD) – a burdensome and often incurable form of dyskinesia. The FDA granted this application Fast Track, Priority Review and Breakthrough Therapy designations.
Currently, benzodiazepines are used to control symptoms of TD. While benzodiazepines can be effective, their use is limited by the development of tolerance, which requires ever-increasing doses to control TD symptoms. Because of the problems associated with benzodiazepines, Ingrezza is set to make a huge impact on those suffering from
AbbVie Inc. (ABBV) released encouraging dataÂ WednesdayÂ for women with chronic pelvic pain, due to endometriosis, who are waiting for a treatment that can improve the quality of their lives.
The data demonstrate that elagolix in premenopausal women who suffer from endometriosis significantly reduces the menstrual pain (dysmenorrhea, DYS) and the nonmenstrual pelvic pain (NMPP). These important results have been announced by AbbVie in cooperation with Neurocrine Biosciences Inc. (NBIX) since Neurocrine licensed the worldwide rights to elagolix to Abbott Labs in June 2010.
Endometriosis is a disease in which tissue that normally lines the inside of the
Neurocrine Biosciences (NBIX) is a pharmaceutical company with two development-stage programs focused on neurological and endocrine-based health problems. The company came to our attention after poor clinical trial results for one of its programs resulted in a 40% reduction in the share price. We invested because the issues with the trial were related to trial design, not drug efficacy. Management presented a credible plan for addressing the design issues, and the company’s valuation was capturing only a fraction of the potential cash flows that could be generated by both drug programs. Over the past year, both of Neurocrine’s drug programs
During the one-year period ending June 30, 2015, the Meridian Contrarian Fund Legacy Class shares returned 6.84%, which compares to a return of 5.92% for its primary benchmark, the Russell 2500 Index.
Performance in the period was aided by the strength of our investments in the financial and energy sectors, as well as by avoiding the utility sector, which was among the weaker sectors in the benchmark.
Our financial holdings are mainly high-quality companies that will benefit from higher interest rates. Interest rates have been near historic lows for an extended period of time, a condition that has hurt the
According to GuruFocus Insider Data, the largest insider sells during the past week were: Oracle Corporation, Time Warner Cable Inc, Facebook Inc, and Neurocrine Biosciences Inc.Â
The overall trend of insiders is illustrated in the chart below:
Oracle Corporation (ORCL): EVP-Product Development Thomas Kurian sold 1,600,000 Shares
EVP-Product DevelopmentÂ Thomas KurianÂ sold 1,600,000 shares of ORCL stock over the past week. Thomas Kurian owns at least 32,327 shares after this. The price of the stock has increased by 0.82% since.
Oracle Corporation was incorporated in 2005 as a Delaware corporation and is
|2020-12-01 $ 94.83 (-0.12%)|
|2020-11-17 $ 91.75 (-1.3%)|
|2020-11-13 $ 91.98 (1.69%)|
|2020-11-10 $ 87.58 (-14.81%)|
|2020-11-09 $ 102.81 (6.72%)|
|2020-11-02 $ 95.98 (-2.73%)|
Neurocrine (NBIX) to Report Q3 Earnings: What's in Store? - www.zacks.com
|2020-10-19 $ 100.69 (-1.78%)|
New Strong Sell Stocks for October 19th - www.zacks.com
|2020-10-16 $ 102.51 (2.68%)|
New Strong Sell Stocks for October 16th - www.zacks.com
|2020-09-15 $ 104.3 (-1.63%)|
|2020-09-14 $ 106.03 (5.62%)|
|2020-09-11 $ 100.39 (-2.53%)|
|2020-08-04 $ 120.16 (-2.32%)|
How Neurocrine Biosciences Crushed It in Q2 - www.fool.com
|2020-08-03 $ 123.01 (2.2%)|
|2020-07-27 $ 126 (0.64%)|
|2020-07-24 $ 125.2 (-2.3%)|
|2020-07-23 $ 128.15 (-1.74%)|
3 Stocks With Momentum Anomaly to Buy This Earnings Season - www.zacks.com
|2020-07-14 $ 131.12 (4%)|
MediWound (MDWD) Jumps: Stock Rises 9.4% - www.zacks.com
|2020-06-25 $ 128.47 (2.48%)|
The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY - www.zacks.com
|2020-06-24 $ 125.36 (-1.81%)|
3 Stocks to Buy on New Drug Approvals by FDA - www.zacks.com
|2020-06-18 $ 121.03 (1.48%)|
|2020-06-17 $ 119.27 (0.32%)|
Neurocrine Adds to Pipeline With $2 Billion Takeda Deal - GuruFocus.com
|2020-06-09 $ 118.82 (0.26%)|
|2020-06-01 $ 123.4 (-1.09%)|
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding - www.zacks.com
|2020-05-14 $ 111.65 (-2.08%)|
Is Now a Good Time To Buy Neurocrine Biosciences? - www.fool.com
|2020-05-12 $ 113.57 (3.81%)|
|2020-05-08 $ 108.94 (5.28%)|
Neurocrine Biosciences Q1 Beats on Earnings, Revenue - www.fool.com
|2020-05-07 $ 108.94 (5.28%)|
|2020-05-06 $ 103.48 (1.67%)|
|2020-05-05 $ 101.78 (2.41%)|
|2020-04-29 $ 100.91 (2.31%)|
|2020-04-27 $ 101.67 (3.55%)|
FDA Approves Neurocrine Biosciences' Parkinson's Drug - www.fool.com
|2020-03-26 $ 92.52 (2.54%)|
COLL or NBIX: Which Is the Better Value Stock Right Now? - www.zacks.com
|2020-02-08 $ 103.98 (1.05%)|
|2020-02-07 $ 103.98 (1.05%)|
|2019-01-25 $ 90.36 (1.53%)|
Neurocrine Biosciences Looks Oversold - GuruFocus.com
|2017-05-19 $ 52.79 (-1.47%)|
What Drug Approval Means for Neurocrine Biosciences - GuruFocus.com
|2015-08-31 $ 46.38 (-0.62%)|
Meridian Funds Comments on Neurocrine Biosciences - GuruFocus.com
Meridian Contrarian Fund Annual Report 2015 - GuruFocus.com
|2011-03-02 $ 6.57 (0.15%)|
|2010-10-29 $ 8.14 (-0.97%)|
|2010-07-29 $ 5.42 (-0.73%)|
|2010-04-29 $ 3.22 (-1.23%)|
|2010-03-04 $ 2.63 (2.73%)|
|2010-01-14 $ 2.55 (1.19%)|
|2009-07-30 $ 3.33 (-1.77%)|
|2009-05-06 $ 3.21 (-3.02%)|